Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Allison

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Gastroenterology|August 24, 2018
Potential Intended and Unintended Consequences of Recommending Initiation of Colorectal Cancer Screening at Age 45 YearsPeter S Liang, James Allison, Uri Ladabaum, et al.
Frontiers in Immunology|October 29, 2025
Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in an <i>in-vivo</i> model of xeno-GvHDGhenima Ahmil-Boiteau, Pranjali Dalvi, Kevin Dang, et al.
Journal for Immunotherapy of Cancer|December 18, 2019
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancerErminia Massarelli, Vincent K Lam, Edwin R Parra, et al.
Journal of the National Cancer Institute|April 1, 2014
Challenges and possible solutions to colorectal cancer screening for the underservedSamir Gupta, Daniel A Sussman, Chyke A Doubeni, et al.
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
Mabs|July 22, 2022
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activityHarshad S Ugamraj, Kevin Dang, Laure-Hélène Ouisse, et al.
American Journal of Respiratory and Critical Care Medicine|February 10, 2007
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary diseaseStephen I Rennard, Charles Fogarty, Steven Kelsen, et al.
The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.
Blood Advances|October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLNitin Jain, Jayastu Senapati, Beenu Thakral, et al.
The Lancet. Oncology|February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyVan K Morris, Mohamed E Salem, Halla Nimeiri, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Gastroenterology|August 24, 2018
Potential Intended and Unintended Consequences of Recommending Initiation of Colorectal Cancer Screening at Age 45 YearsPeter S Liang, James Allison, Uri Ladabaum, et al.
Frontiers in Immunology|October 29, 2025
Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in an <i>in-vivo</i> model of xeno-GvHDGhenima Ahmil-Boiteau, Pranjali Dalvi, Kevin Dang, et al.
Journal for Immunotherapy of Cancer|December 18, 2019
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancerErminia Massarelli, Vincent K Lam, Edwin R Parra, et al.
Journal of the National Cancer Institute|April 1, 2014
Challenges and possible solutions to colorectal cancer screening for the underservedSamir Gupta, Daniel A Sussman, Chyke A Doubeni, et al.
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
Mabs|July 22, 2022
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activityHarshad S Ugamraj, Kevin Dang, Laure-Hélène Ouisse, et al.
American Journal of Respiratory and Critical Care Medicine|February 10, 2007
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary diseaseStephen I Rennard, Charles Fogarty, Steven Kelsen, et al.
The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.
Blood Advances|October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLNitin Jain, Jayastu Senapati, Beenu Thakral, et al.
The Lancet. Oncology|February 23, 2017
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 studyVan K Morris, Mohamed E Salem, Halla Nimeiri, et al.
Pageof 4